Categories
Change Password!
Reset Password!
Combining ixekizumab with tirzepatide improves complete skin clearance and weight reduction compared with ixekizumab alone in adults with psoriasis and overweight or obesity.
For decades, dermatologists have faced a persistent bottleneck: up to 78% of people with psoriasis also struggle with overweight or obesity, a metabolic overlap that not only worsens skin inflammation but actively blunts the performance of targeted biologics. Now, the outcomes of a pivotal phase 3b clinical trial reveal a dual-target strategy that tackles both diseases head-on.
By pairing the interleukin-17A inhibitor ixekizumab with the dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonist tirzepatide, researchers demonstrated that simultaneous immune suppression and metabolic resetting can attain outcomes that standard monotherapy simply cannot match. The 52-week, open-label, randomised clinical trial enrolled 274 adults across 72 sites in the United States. Subjects were assigned in a 1:1 ratio to receive:
Both groups also received diet and exercise interventions. The primary endpoint was the simultaneous achievement of 100% improvement in the Psoriasis Area and Severity Index (PASI 100) and at least 10% weight reduction at week 36. Among the participants, 231 (84.3%) completed treatment through week 36. The key findings were:
The reported adverse events largely aligned with the known safety profiles of both medications, with no novel safety signals identified. Gastrointestinal events occurred more frequently with combination therapy. The most commonly noted events included:
Injection-site reactions occurred at similar rates in both groups (12.3% vs. 12.7%). No deaths were reported. The findings highlight the potential value of addressing obesity alongside psoriasis rather than focusing exclusively on skin manifestations. Combining ixekizumab with tirzepatide improved complete skin clearance, promoted substantial weight loss, and offered additional metabolic benefits. Hence, this combination appears to offer a promising approach for adults with moderate-to-severe plaque psoriasis and overweight or obesity.
JAMA Dermatology
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity A Phase 3b Randomized Clinical Trial
Mark Lebwohl et al.
Comments (0)